A Technical Comparison of Human Papillomavirus Genotyping Assays from a Population-Based Cervical Cancer Screening in South Central Ethiopia

References

• World Health Organization - International Agency for Research on Cancer. Globocan 2020 - Cervix uteri; 2020:2–3. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdf. Accessed July 14, 2022.
   Google Scholar
• Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890–907. doi:10.1016/S0140-6736(07)61416-0
   PubMed Web of Science ®Google Scholar
• Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nature Rev Cancer. 2019;18(4):240–254. doi:10.1038/nrc.2018.13.Opportunities
   Web of Science ®Google Scholar
• Federal Democratic Republic of Ethiopia Ministry of Health. Guideline for cervical cancer prevention and control in Ethiopia; 2015.
   Google Scholar
• Gizaw M, Teka B, Ruddies F, et al. Reasons for not attending cervical cancer screening and associated factors in Rural Ethiopia. Cancer Prev Res. 2020;13(7):593–599. doi:10.1158/1940-6207.CAPR-19-0485
   PubMed Web of Science ®Google Scholar
• Gizaw M, Teka B, Ruddies F, et al. Uptake of cervical cancer screening in Ethiopia by self-sampling HPV DNA compared to visual inspection with acetic acid: a cluster randomized trial. Cancer Prev Res. 2019;12(9):609–616. doi:10.1158/1940-6207.CAPR-19-0156
   PubMed Web of Science ®Google Scholar
• Chauhan AS, Prinja S, Srinivasan R, et al. Cost effectiveness of strategies for cervical cancer prevention in India. PLoS One. 2020;15(9):e0238291. doi:10.1371/journal.pone.0238291
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–19. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
   PubMed Web of Science ®Google Scholar
• Dijkstra MG, van Zummeren M, Rozendaal L, et al. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ. 2016;355:i4924. doi:10.1136/bmj.i4924
   PubMed Web of Science ®Google Scholar
• Arbyn M, de Sanjose S, Saraiya M, et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer. 2012;131(9):1969–1982. doi:10.1002/ijc.27650
   PubMed Web of Science ®Google Scholar
• Cuzick J, Adcock R, Wheeler CM. HPV genotype-specific risk for cervical cancer; 2021. Available from: www.HPVWorld.com. Accessed July 14, 2022.
   Google Scholar
• Arbyn M, Simon M, Peeters E, et al. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect. 2021;27(8):1083–1095. doi:10.1016/j.cmi.2021.04.031
   PubMed Web of Science ®Google Scholar
• World Health Organisation. WHO Guideline for Screening and Treatment of Cervical Pre-Cancer Lesions for Cervical Cancer Prevention. 2nd ed. Geneva: World Health Organisation; 2021.
   Google Scholar
• Poljak M, Oštrbenk Valenčak A, Gimpelj Domjanič G, Xu L, Arbyn M. Commercially available molecular tests for human papillomaviruses: a global overview. Clin Microbiol Infect. 2020;26(9):1144–1150. doi:10.1016/j.cmi.2020.03.033
   PubMed Web of Science ®Google Scholar
• Elfgren K, Elfström KM, Naucler P, Arnheim-Dahlström L, Dillner J. Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial. Am J Obstet Gynecol. 2017;216(3):264.e1–264.e7. doi:10.1016/j.ajog.2016.10.042
   PubMed Web of Science ®Google Scholar
• Jones J, Powell NG, Tristram A, Fiander AN, Hibbitts S. Comparison of the PapilloCheck® DNA micro-array human papillomavirus detection assay with hybrid capture II and PCR-enzyme immunoassay using the GP5/6+ primer set. J Clin Virol. 2009;45(2):100–104. doi:10.1016/j.jcv.2009.02.013
   PubMed Web of Science ®Google Scholar
• Arbyn M, Snijders PJF, Meijer CJLM, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect. 2015;21(9):817–826. doi:10.1016/j.cmi.2015.04.015
   PubMed Web of Science ®Google Scholar
• Maver PJ, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect. 2020;26(5):579–583. doi:10.1016/j.cmi.2019.09.006
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Holme F. What is needed now for successful scale-up of screening? Papillomavirus Res. 2019;7:173–175. doi:10.1016/j.pvr.2019.04.011
   PubMed Web of Science ®Google Scholar
• Poljak M, Kocjan BJ, Oštrbenk A, Seme K. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. J Clin Virol. 2016;76:S3–S13. doi:10.1016/j.jcv.2015.10.023
   PubMed Web of Science ®Google Scholar
• Abreu ALP, Souza RP, Gimenes F, Consolaro MEL. A review of methods for detect human Papillomavirus infection. Virol J. 2012;9:1–9. doi:10.1186/1743-422X-9-262
   PubMed Web of Science ®Google Scholar
• Teka B, Gizaw M, Ruddies F, et al. Population-based human papillomavirus infection and genotype distribution among women in rural areas of South Central Ethiopia. Int J Cancer. 2021;148(3):723–730. doi:10.1002/ijc.33278
   PubMed Web of Science ®Google Scholar
• Schmitt M, Dondog B, Waterboer T, Pawlita M. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5 ϩ and GP6 ϩ primers. J Clin Microbiol. 2008;46(3):1050–1059. doi:10.1128/JCM.02227-07
   PubMed Web of Science ®Google Scholar
• Geraets DT, Cuschieri K, De Koning MNC, et al. Clinical evaluation of a GP5+/6+-based Luminex assay having full high-risk human papillomavirus genotyping capability and an internal control. J Clin Microbiol. 2014;52(11):3996–4002. doi:10.1128/JCM.01962-14
   PubMed Web of Science ®Google Scholar
• Cornall AM, Poljak M, Garland SM, et al. EUROarray human papillomavirus (HPV) assay is highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities. Eur J Clin Microbiol Infect Dis. 2016;35(6):1033–1036. doi:10.1007/s10096-016-2634-8
   PubMed Web of Science ®Google Scholar
• Hesselink AT, Sahli R, Berkhof J, et al. Clinical validation of AnyplexTM II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening. J Clin Virol. 2016;76:36–39. doi:10.1016/j.jcv.2016.01.009
   PubMed Web of Science ®Google Scholar
• Landis JR, Koch GG. Landis and Koch 1977_agreement of categorical data. Biometrics. 1977;33(1):159–174. doi:10.2307/2529310
   PubMed Web of Science ®Google Scholar
• Arbyn M, Hillemanns P. HPV assays validated for primary cervical cancer screening. HPV World. 2018;55:6–9.
   Google Scholar
• Wentzensen N, Arbyn M, Berkhof J, et al. Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. Int J Cancer. 2017;140(10):2192–2200. doi:10.1002/ijc.30579
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Strategy Towards the Elimination of Cervical Cancer as a Public Health Problem. World Health Organization; 2019:1–24.
   Google Scholar
• Arbyn M, Depuydt C, Benoy I, et al. VALGENT: a protocol for clinical validation of human papillomavirus assays. J Clin Virol. 2016;76(Suppl 1):S14–S21. doi:10.1016/j.jcv.2015.09.014
   PubMed Web of Science ®Google Scholar
• Cornall AM, Poljak M, Garland SM, et al. HPV genotype-specific concordance between EuroArray HPV, Anyplex II HPV28 and linear array HPV genotyping test in Australian cervical samples. Papillomavirus Res. 2017;4:79–84. doi:10.1016/j.pvr.2017.10.002
   PubMed Web of Science ®Google Scholar
• Donà MG, Benevolo M, Pimpinelli F, et al. Comparative evaluation of different DNA extraction methods for HPV genotyping by linear array and INNO-LiPA. J Med Virol. 2011;83(6):1042–1047. doi:10.1002/jmv.22088
   PubMed Web of Science ®Google Scholar
• Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1–17. doi:10.1128/CMR.16.1.1-17.2003
   PubMed Web of Science ®Google Scholar
• IARC WG. International Agency for Research on Cancer IARC monographs on the evaluation of carcinogenic risks to humans volume 90 human papillomaviruses; 2007. Available from: http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Monographs+on+the+Evaluation+of+Carcinogenic+Risks+to+Humans+VOLUME+90+Human+Papillomaviruses#0. Accessed July 14, 2022.
   Google Scholar
• Trevethan R. Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice. Front Public Heal. 2017;5:1–7. doi:10.3389/fpubh.2017.00307
   PubMed Web of Science ®Google Scholar
• Saah AJ, Hoover DR. “Sensitivity” and “specificity” reconsidered: the meaning of these terms in analytical and diagnostic settings. Ann Intern Med. 1997;126(1):91–94. doi:10.7326/0003-4819-126-1-199701010-00026
   PubMed Web of Science ®Google Scholar
• Kinney W, Stoler MH, Castle PE. Patient safety and the next generation of HPV DNA tests. Am J Clin Pathol. 2010;134(2):193–199. doi:10.1309/AJCPRI8XPQUEAA3K
   PubMed Web of Science ®Google Scholar